What question did this study set out to answer?

The aim is to assess the effects of omalizumab, SCIT-HDM, and their combination on allergic asthma over three years.

April 17, 2026Journal of Asthma1 citations

Three years treatment with HDM allergen immunotherapy, omalizumab, or combination therapy in allergic asthma: clinical outcomes and biomarkers

ABAndrzej BożekMedical University of Silesia MMMartyna MiodonskaMedical University of Silesia DSDominika SadowskaMedical University of Silesia

Key Points

The aim is to assess the effects of omalizumab, SCIT-HDM, and their combination on allergic asthma over three years.
Comparison of omalizumab, SCIT-HDM, and combination therapy over 36 months.
Evaluation of clinical outcomes associated with each treatment.
Analysis of biomarkers to understand treatment effects.
Combination therapy showed the most consistent clinical benefits.
Both omalizumab and SCIT-HDM improved outcomes compared to baseline.
Results should be interpreted with caution due to small sample size.

Abstract

Omalizumab, SCIT-HDM, and their combination improved outcomes over 36 months. Combination therapy showed the most consistent benefits, but results should be interpreted cautiously due to the small sample size. Further studies are needed.

Demander à l'IA

Bookmark

View Full Paper

Cite This Study

Bożek et al. (Wed,) studied this question.

synapsesocial.com/papers/69e1ce605cdc762e9d85760d https://doi.org/https://doi.org/10.1080/02770903.2026.2660096

Demander à l'IA

Bookmark

View Full Paper